Skip to main content

Pembrolizumab + Standard Chemotherapy Beneficial in Mesothelioma

Medically reviewed by Carmen Pope, BPharm. Last updated on Nov 15, 2023.

By Elana Gotkine HealthDay Reporter

WEDNESDAY, Nov. 15, 2023 -- The addition of pembrolizumab to standard platinum-pemetrexed chemotherapy results in significant improvement in overall survival among patients with advanced pleural mesothelioma, according to a study published online Nov. 3 in The Lancet.

Quincy Chu, M.D., from the Cross Cancer Institute in Edmonton, Alberta, Canada, and colleagues conducted an open-label, randomized trial at 51 hospitals involving adults with previously untreated advanced pleural mesothelioma. Patients were randomly assigned to receive intravenous chemotherapy (cisplatin or carboplatin with pemetrexed) with or without intravenous pembrolizumab (222 and 218 patients, respectively).

The researchers found that overall survival was significantly longer with pembrolizumab than chemotherapy alone (median overall survival, 17.3 versus 16.1 months; hazard ratio for death, 0.79). The three-year overall survival rate was 25 and 17 percent with pembrolizumab and chemotherapy alone, respectively. Study treatment-related grade 3 or 4 adverse events occurred in 27 percent of patients in the pembrolizumab group and 15 percent in the chemotherapy group; hospital admissions for study drug-related serious adverse events were reported in 18 and 6 percent of patients, respectively. Two patients in the pembrolizumab group and one in the chemotherapy group reported grade 5 adverse events related to one or more drugs.

"The addition of pembrolizumab to platinum-pemetrexed was a tolerable regimen that did not lead to a detriment in quality of life despite increased toxicity and that resulted in improved overall survival, progression-free survival, and objective response rates compared with platinum and pemetrexed chemotherapy," the authors write.

Several authors disclosed ties to pharmaceutical companies, including Merck, which manufactures pembrolizumab and partially funded the study.

Abstract/Full Text (subscription or payment may be required)

Editorial (subscription or payment may be required)

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

© 2024 HealthDay. All rights reserved.

Posted November 2023

Read this next

Pegargiminase + Chemo Increases Survival Rate in Nonepithelioid Pleural Mesothelioma

FRIDAY, Feb. 23, 2024 -- For patients with nonepithelioid pleural mesothelioma, pegargiminase plus chemotherapy is associated with improved survival versus placebo plus...

More news resources

Subscribe to our newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.